Receive Free Email Alerts on RXi Pharmaceuticals:

First Name:
Last Name:

Sign up for free email alerts including press releases, in-depth featured articles, SEC Filing alerts, Presentation Schedules and Trading Alerts.

RXi Pharmaceuticals Corporation (RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or “RNAi,” have great promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi’s first RNAi product candidate, RXI-109, which targets CTGF, entered into human clinical development in June 2012.

Emerging Growth Corp has been compensated for the production and promotion of this site. Read the full compensation disclaimer here